Back to News
Market Impact: 0.1

DGRO ETF Factor Report

DGRONDAQ
Capital Returns (Dividends / Buybacks)Derivatives & VolatilityCompany FundamentalsAnalyst InsightsHealthcare & Biotech
DGRO       ETF Factor Report

Validea's fundamental report characterizes the iShares Core Dividend Growth ETF (DGRO) as a Large-Cap Low Volatility ETF, scoring highly in Quality (88/99) and Low Volatility (90/99). With its largest exposures in the Financial sector and Biotechnology & Drugs industry, DGRO exhibits moderate Value (58/99) but low Momentum (41/99), positioning it as a quality- and stability-focused investment rather than a momentum-driven play.

Analysis

The iShares Core Dividend Growth ETF (DGRO) is characterized by a strong defensive profile, according to Validea's fundamental factor report. The ETF scores exceptionally high on Quality (88/99) and Low Volatility (90/99), indicating its underlying holdings are fundamentally sound and historically less prone to price swings. This aligns with its classification as a Large-Cap Low Volatility ETF. In contrast, its exposure to Momentum is notably low at 41/99, suggesting the fund is not constructed to chase current market trends. The Value factor exposure is moderate at 58/99. Portfolio composition is concentrated, with the Financial sector and the Biotechnology & Drugs industry representing the largest respective exposures. This factor profile positions DGRO as a vehicle for investors prioritizing stability and fundamental strength over high-growth or momentum-based strategies.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

mildly positive

Sentiment Score

0.30

Ticker Sentiment

DGRO0.60
NDAQ0.00

Key Decisions for Investors

  • Investors seeking defensive equity exposure with an emphasis on high-quality companies and lower price volatility may find DGRO's factor profile attractive.
  • Given the low Momentum score of 41, this ETF may underperform in strongly trending bull markets, so it should be balanced against growth-oriented holdings in a diversified portfolio.
  • The significant concentration in the Financial and Biotechnology & Drugs sectors warrants a review of an investor's existing sector exposures to avoid unintended overweights.
  • Consider this ETF for core long-term holdings focused on dividend growth and capital preservation, rather than for short-term tactical plays capitalizing on market momentum.